Explore the words cloud of the IB4SD-TRISTAN project. It provides you a very rough idea of what is the project "IB4SD-TRISTAN" about.
The following table provides information about the project.
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
|Coordinator Country||Belgium [BE]|
|Total cost||22˙641˙050 €|
|EC max contribution||12˙000˙000 € (53%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2017-01-01 to 2021-12-31|
Take a look of project's partnership.
|1||EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL||BE (Brussels)||coordinator||1˙241˙601.00|
|2||BIOXYDYN LIMITED||UK (MANCHESTER)||participant||1˙991˙627.00|
|3||UNIVERSITY OF LEEDS||UK (LEEDS)||participant||1˙367˙686.00|
|4||THE UNIVERSITY OF MANCHESTER||UK (MANCHESTER)||participant||1˙361˙022.00|
|5||STICHTING KATHOLIEKE UNIVERSITEIT||NL (NIJMEGEN)||participant||1˙310˙232.00|
|6||ACADEMISCH ZIEKENHUIS GRONINGEN||NL (GRONINGEN)||participant||1˙099˙795.00|
|7||THE UNIVERSITY OF SHEFFIELD||UK (SHEFFIELD)||participant||994˙512.00|
|8||TRULY LABS AB||SE (LUND)||participant||644˙712.00|
|9||LUNDS UNIVERSITET||SE (LUND)||participant||609˙785.00|
|10||ANTAROS MEDICAL AB||SE (MOLNDAL)||participant||566˙025.00|
|11||CHALMERS TEKNISKA HOEGSKOLA AB||SE (GOETEBORG)||participant||563˙003.00|
|12||UNIVERSITE DIJON BOURGOGNE||FR (DIJON CEDEX)||participant||250˙000.00|
|13||ABBVIE DEUTSCHLAND GMBH & CO KG||DE (WIESBADEN)||participant||0.00|
|14||Bayer Pharma AG||DE (Berlin)||participant||0.00|
|15||BRUKER BIOSPIN MRI GMBH||DE (ETTLINGEN)||participant||0.00|
|16||GE HEALTHCARE LIMITED||UK (LITTLE CHALFONT)||participant||0.00|
|17||GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.||UK (BRENTFORD)||participant||0.00|
|18||MERCK SHARP & DOHME CORP||US (WHITEHOUSE STATION NJ)||participant||0.00|
|19||NOVO NORDISK A/S||DK (BAGSVAERD)||participant||0.00|
|20||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|21||SANOFI-AVENTIS DEUTSCHLAND GMBH||DE (FRANKFURT AM MAIN)||participant||0.00|
1.Our consortium has broad, deep experience of drug development and imaging biomarker (IB) validation. We are internationally recognized experts in transporter biology, animal models of lung injury, toxicology, DCEMRI, compartmental modeling, 1H&129Xe lung MR, and labeling of biologicals with PET and fluorescence tags, together with physicians who care for relevant patients. We have an outstanding record of translating IBs: (a) into animals, (b) into man, (c) into tools which drug developers use with confidence in clinical trials of investigational agents, (d) into regulatory drug development and healthcare. We will develop and validate the required IBs and make them commercially available. 2.Building on our previous work with gadoxetate DCEMRI IBs we will develop and standardise, define sensitivity and specificity in rats, and show valid and comparable data multicentre in human volunteers and patients. 3.We believe the search for IBs of Drug Induced Interstitial Lung Disease (DIILD) should start in DIILD patients. Cancer and rheumatology patients receiving, in their standard care, drugs with DIILD liability, and whose physicians withdraw the drug due to suspected DIILD, will be imaged when symptomatic and followed up. From this we will derive IBs of DIILD which predict outcome. We will also develop IBs from 1H/129Xe MRI and PET to further characterise DIILD, and will back-translate and validate all these IBs in rat models. 4.To better assess biodistribution of biologics, we will thoroughly characterise two well-chosen exemplars in rats, pigs and humans: an antibody biologic and a peptide biologic. We will use 89Zr, 18F and 68Ga PET, fluorescence and MALDI imaging. 5.We will follow an imaging biomarker roadmap to establish (a) that the IBs can be deployed robustly in whatever centre they are needed, (b) the relationship of the IB to underlying biology, (c) how well the IB forecasts clinical outcome, and make appropriate arrangements for dissemination.
|Free-breathing 3D acquisition protocol for pre-clinical MRI||Websites, patent fillings, videos etc.||2020-04-24 02:25:35|
|Manuscript on the progression of bleomycin induced inflammation and fibrosis in rats imaged by MRI/CT||Documents, reports||2020-04-24 02:25:35|
|Manuscript on novel 89Zr chelates for protein labeling||Documents, reports||2020-04-24 02:25:35|
|Manuscript for phantom imaging reproducibility||Documents, reports||2020-04-24 02:25:35|
|Manuscript for reviews on ILD imaging in humans||Documents, reports||2020-04-24 02:25:35|
|Free-breathing 3D acquisition protocol for clinical MRI||Websites, patent fillings, videos etc.||2020-04-24 02:25:35|
|Gadoxetate imaging model software||Websites, patent fillings, videos etc.||2020-04-24 02:25:35|
|Manuscript for a review on current 89Zr chelates for protein labeling||Documents, reports||2020-04-24 02:25:34|
|Review 1 for liver transporter assessment by imaging||Documents, reports||2020-04-24 02:25:34|
|Phantom QC for clinical MRI scanner stability over time||Websites, patent fillings, videos etc.||2020-04-24 02:25:34|
|optimized data acquisition of 129 Xe MRI||Websites, patent fillings, videos etc.||2020-04-24 02:25:34|
|Workplan for pre-clinical BSEP-probe evaluation||Documents, reports||2020-04-24 02:25:34|
|Phantom QC for rat MRI scanner stability over time||Websites, patent fillings, videos etc.||2020-04-24 02:25:34|
|Open-access website for validation SOP download||Websites, patent fillings, videos etc.||2020-04-24 02:25:34|
Take a look to the deliverables list in detail: detailed list of IB4SD-TRISTAN deliverables.
|year||authors and title||journal||last update|
Sandra Heskamp, RenÃ© RaavÃ©, Otto Boerman, Mark Rijpkema, Victor Goncalves, Franck Denat
89 Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art 89 Zr Radiochemistry
published pages: 2211-2223, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00325
|Bioconjugate Chemistry 28/9||2020-04-24|
Sarah Skeoch, Nicholas Weatherley, Andrew Swift, Alexander Oldroyd, Christopher Johns, Conal Hayton, Alessandro Giollo, James Wild, John Waterton, Maya Buch, Kim Linton, Ian Bruce, Colm Leonard, Stephen Bianchi, Nazia Chaudhuri
Drug-Induced Interstitial Lung Disease: A Systematic Review
published pages: 356, ISSN: 2077-0383, DOI: 10.3390/jcm7100356
|Journal of Clinical Medicine 7/10||2020-04-24|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IB4SD-TRISTAN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IB4SD-TRISTAN" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist DrugRead More
Antibiotic Distribution and Recovery in TissueRead More